| Project | Regeling | Bedrag | Jaar | Actie |
|---|---|---|---|---|
Destruction of forever chemicals in water using chemical-free water treatment systemFOREVER-WATER aims to develop and validate graphene-enabled electrochemical systems for sustainable PFAS removal from contaminated water, paving the way for commercialization and addressing environmental health risks. | EIC Transition | € 2.487.471 | 2025 | Details |
EndocartoScope: Transforming any Endoscope into a Smart Device for Intraoperative 3D Localization, Navigation and MappingEndoCartoScope aims to develop a real-time 3D mapping system for endoscopy using VSLAM technology, enhancing navigation and measurement for improved diagnostics and future robotic applications. | EIC Transition | € 2.498.425 | 2025 | Details |
Integrated Quantum Network Node using Chip-based Qubit DevicesDelft Networks aims to develop scalable quantum networking technology and services to demonstrate real-world applications, enhancing societal and economic value through innovative quantum connectivity. | EIC Transition | € 2.499.999 | 2025 | Details |
Radically New Cancer Therapy Based on Advances in Nanotechnology and Photonics for Simultaneous Imaging and Treatment of Solid TumoursScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027. | EIC Transition | € 2.499.911 | 2025 | Details |
Perovskite Photon Counting X-ray Detectors for Medical Imaging.Clarity Sensors is developing advanced photon-counting detectors using halide perovskite semiconductors to enhance X-ray imaging resolution while reducing radiation dose, aiming for widespread adoption in clinical settings. | EIC Transition | € 2.494.268 | 2025 | Details |
Advancing stroke care with cutting-edge ultrasound biomarkers for Neurocritical CareResolve Stroke aims to enhance ultrasound imaging with the SYLVER system to improve stroke diagnosis and management through innovative biomarkers, making timely detection more accessible and effective. | EIC Transition | € 2.493.436 | 2025 | Details |
Breakthrough Neoantigen-specific Tumor-Infiltrating Lymphocyte Therapies Through Novel Dendritic Cell ReprogrammingThe Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization. | EIC Transition | € 2.480.367 | 2025 | Details |
Development and validation of a pan-cancer neutrophil biomarker test for predicting clinical benefit from immunotherapy based on flow cytometry analysis of blood samplesThe NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs. | EIC Transition | € 2.499.999 | 2025 | Details |
Ultralow power ferroelectric spintronic components for logic and artificial intelligenceUPSPRING aims to revolutionize microelectronics by advancing ultra-low energy FESO technology to reduce chip energy consumption by 1000x, enhancing performance and supporting EU semiconductor sovereignty. | EIC Transition | € 2.499.999 | 2025 | Details |
Revolutionizing Skin Health with our Advanced Engineered BiotherapeuticsThe SkinEngineering project aims to advance a patented biotherapeutic technology using genetically engineered skin bacteria for effective acne treatment, targeting regulatory validation and commercialization. | EIC Transition | € 2.499.999 | 2025 | Details |
Direct Coherent Detection Optical TransceiverPhanofi ApS aims to develop a compact 800G transceiver using innovative Fano Detector technology to enhance data center efficiency and support the growing demand for high-speed internet. | EIC Transition | € 2.499.999 | 2025 | Details |
Smart Implant for Magnetic Anastomotic Healing and Leakage EvaluationThe SMARTHEAL project aims to develop a smart magnetic anastomosis implant with integrated micro-sensors for enhanced healing and early detection of leaks, improving surgical outcomes and reducing costs. | EIC Transition | € 2.499.815 | 2025 | Details |
Anticancer approach based on the Metabolic Disruption of Cancer Stem Cells with high effectivity across a wide range of solid tumoursThe project aims to develop the novel anticancer agent IGN116, targeting cancer stem cells in CRC and PDAC, to provide effective treatment with low toxicity, benefiting thousands of patients by 2040. | EIC Transition | € 2.498.015 | 2025 | Details |
Scalable Qubit Readout to Resolve Superconducting Quantum Computing’s Skeleton in the ClosetSilent Waves aims to revolutionize qubit readout in quantum computing with a compact Traveling Wave Parametric Amplifier, enhancing scalability and performance for practical quantum processors. | EIC Transition | € 2.479.570 | 2025 | Details |
Polymer-based Stealth Coating of Hemocompatible and Absorbable StentsThe StealthStent project aims to create a resorbable stent for pediatric congenital heart disease, reducing foreign body reactions and improving treatment outcomes for children and adults. | EIC Transition | € 2.495.679 | 2025 | Details |
Wireless, Low-Cost, Low-Power Integrated Sensor PhotonicsWILLOWISP aims to develop a compact, cost-effective methane gas analyser using innovative photonic chips, enhancing leak detection in fossil fuel infrastructure. | EIC Transition | € 2.495.031 | 2025 | Details |
Enabling the transition to 3D digital pathology3DPATH aims to develop a clinically viable 3D tissue scanner using advanced light-sheet fluorescence microscopy to enhance histopathology accuracy and improve patient care globally. | EIC Transition | € 2.493.683 | 2025 | Details |
VIVA-ELISA: Advanced Laboratory Test for Rapid Detection of NLRP3 Inflammasome Activation in Critical Septic PatientsVIVA-ELISA aims to develop a rapid, sensitive immunoassay for early detection of NLRP3 inflammasome impairment in sepsis patients to reduce mortality by 25-40% and improve treatment outcomes. | EIC Transition | € 2.493.003 | 2025 | Details |
ARISE - Advanced RNA Inhalation Solutions anchored in Evolved dry powder technology.RNhale's project aims to revolutionize RNA therapeutics for pulmonary diseases by developing inhalable dry powder formulations of RNA encapsulated in lipid nanoparticles. | EIC Transition | € 2.421.498 | 2025 | Details |
RESTORING IMMUNITY CONTROL OF GI CANCERSTIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization. | EIC Transition | € 2.007.750 | 2025 | Details |
FOREVER-WATER aims to develop and validate graphene-enabled electrochemical systems for sustainable PFAS removal from contaminated water, paving the way for commercialization and addressing environmental health risks.
EndoCartoScope aims to develop a real-time 3D mapping system for endoscopy using VSLAM technology, enhancing navigation and measurement for improved diagnostics and future robotic applications.
Delft Networks aims to develop scalable quantum networking technology and services to demonstrate real-world applications, enhancing societal and economic value through innovative quantum connectivity.
ScanNanoTreat aims to revolutionize cancer treatment by integrating advanced imaging and therapy technologies to improve patient outcomes and reduce costs, targeting clinical trials by 2027.
Clarity Sensors is developing advanced photon-counting detectors using halide perovskite semiconductors to enhance X-ray imaging resolution while reducing radiation dose, aiming for widespread adoption in clinical settings.
Resolve Stroke aims to enhance ultrasound imaging with the SYLVER system to improve stroke diagnosis and management through innovative biomarkers, making timely detection more accessible and effective.
The Repro-TIL project aims to enhance tumor-reactive TIL expansion for more effective immunotherapy in solid tumors, paving the way for improved treatment outcomes and commercialization.
The NeutroFlow project aims to develop a non-invasive blood test using a flow cytometry assay to predict cancer immunotherapy benefits, enhancing patient outcomes and reducing costs.
UPSPRING aims to revolutionize microelectronics by advancing ultra-low energy FESO technology to reduce chip energy consumption by 1000x, enhancing performance and supporting EU semiconductor sovereignty.
The SkinEngineering project aims to advance a patented biotherapeutic technology using genetically engineered skin bacteria for effective acne treatment, targeting regulatory validation and commercialization.
Phanofi ApS aims to develop a compact 800G transceiver using innovative Fano Detector technology to enhance data center efficiency and support the growing demand for high-speed internet.
The SMARTHEAL project aims to develop a smart magnetic anastomosis implant with integrated micro-sensors for enhanced healing and early detection of leaks, improving surgical outcomes and reducing costs.
The project aims to develop the novel anticancer agent IGN116, targeting cancer stem cells in CRC and PDAC, to provide effective treatment with low toxicity, benefiting thousands of patients by 2040.
Silent Waves aims to revolutionize qubit readout in quantum computing with a compact Traveling Wave Parametric Amplifier, enhancing scalability and performance for practical quantum processors.
The StealthStent project aims to create a resorbable stent for pediatric congenital heart disease, reducing foreign body reactions and improving treatment outcomes for children and adults.
WILLOWISP aims to develop a compact, cost-effective methane gas analyser using innovative photonic chips, enhancing leak detection in fossil fuel infrastructure.
3DPATH aims to develop a clinically viable 3D tissue scanner using advanced light-sheet fluorescence microscopy to enhance histopathology accuracy and improve patient care globally.
VIVA-ELISA aims to develop a rapid, sensitive immunoassay for early detection of NLRP3 inflammasome impairment in sepsis patients to reduce mortality by 25-40% and improve treatment outcomes.
RNhale's project aims to revolutionize RNA therapeutics for pulmonary diseases by developing inhalable dry powder formulations of RNA encapsulated in lipid nanoparticles.
TIMNano aims to develop a novel cancer immunotherapy platform using targeted biodegradable nanoparticles to enhance immune responses against gastrointestinal cancers, progressing through clinical trials and commercialization.
SubsidieMeesters